Compare Citius Pharmaceuticals Inc (CTXR) vs Deere & Company (DE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Deere & Company — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Deere & Company trades at $632.1 (market cap $175.95B). The key difference: Deere & Company is far larger — about 12918.5× Citius Pharmaceuticals Inc's market cap, and Deere & Company pays a 0.99% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Deere & Company for 75 Days on average.
| CTXR | DE | |
|---|---|---|
Market Cap | $13.62M | $175.95B |
Volume | 132,438 | 1,387,231 |
Sector | Health | Industrials |
52-Week High | $1.82 | $709.48 |
52-Week Low | $0.48 | $439.11 |
Typical Hold Time | 16 Days | 75 Days |
Enterprise Value | $3.79M | $229.85B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Deere & Company (DE) trades at $627.66, down 4.45% on the day, reflecting near-term pressure amid a bearish technical signal. The stock has demonstrated consistent earnings beats in recent quarters, with Q2 2026 EPS of $5.10 surpassing the $4.69 estimate. However, revenue has declined from $60.2B in 2023 to $44.7B in 2025, compressing net margins. Analyst consensus remains optimistic with a $731.20 price target, supported by a 43.48% buy rating.
The outlook balances strong profitability metrics like an 18.4% ROE against cyclical headwinds in the agriculture equipment sector. Key risks include further revenue contraction and high debt levels, but institutional accumulation and a strategic focus on AI-driven farming solutions present long-term growth catalysts. The current valuation at a P/E of 36.27 demands sustained earnings expansion to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
